Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: bobbseytwins2001 who wrote (1201)	10/22/2025 4:07:22 PM
From: jargonweary	Respond to of 1216

Being a market contrarian by nature I do take your point about this possibly being a time to buy. A lot of market wisdom suggests the time to buy is when pessimism is at its highest. Rothschild’s comment about blood in the streets of Paris and all that. This is tempered, of course, by the fact that sometimes the pessimism is justified and proves to be correct. Which is it with IBRX? I am drumming my fingers on the desk trying to reach a decision about that. And honestly, I am just not sure. I am being pulled between serious concerns about PSS and the management of the company versus FOMO.

To: bobbseytwins2001 who wrote (1201)	10/23/2025 12:17:14 PM
From: dorightbythem	1 Recommendation Recommended By erippetoe Read Replies (1) \| Respond to of 1216

Twins I don’t dispute that there are trials, in fact I prefer more trials that deal with PSS’s latest assertions about arming our own immune systems. I would like to see more, clarity and information on overseas approvals and sales. Unfortunately, those updates are few and far between. Another point I fell short of discussing is that there will be no stockholder revolt this time due to an imbalance of shareholder ownership. Furthermore, the balance sheet, lack of funds and slow ramp up of sales leave the company exposed to the shorts. A well warned tale.